Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain

Enferm Infecc Microbiol Clin (Engl Ed). 2019 Jun-Jul;37(6):373-379. doi: 10.1016/j.eimc.2018.09.015. Epub 2018 Oct 30.
[Article in English, Spanish]

Abstract

Background: The life expectancy of HIV-infected individuals has dramatically improved with potent antiretroviral therapies. However, organ-specific toxicities of some antiretrovirals and persistent inflammation and immune activation due to residual virus replication account for a high burden of age-associated comorbidities in the HIV population.

Methods: The prevalence of overt cardiovascular, renal and bone diseases as well as their major risk factors were cross-sectionally examined during the year 2014 in the VACH cohort, a large nationwide population of HIV-infected individuals in Spain.

Results: A total of 10,897 HIV-infected patients were examined. Seventy-one point four percent were male and the mean age was 48 years. Mean time since HIV diagnosis was 15.8 years and mean time on antiretroviral therapy was 13.1 years. The proportion of patients with undetectable viral load was 87.1%, whereas 65.7% had CD4 counts>500 cells/mm3. Overall, cardiovascular, renal and bone disease were recorded in 4.7%, 5.9% and 2.8%, respectively. The prevalence of major risk factors was as follows: smoking 51.3%, alcohol abuse 7.8%, overweight/obesity 42.2%, diabetes 19.9%, dyslipidaemia 72.6%, hypertension 25.6%, and osteoporosis 11.1%. In the subset of patients older than 55 years-old (18%), all figures for overt disease and their major risk factors were significantly greater.

Conclusion: Major age-related medical conditions and most of their risk factors are highly prevalent in HIV-infected individuals on long-term antiretroviral therapy in Spain. Preventive actions, including careful selection of antiretroviral agents, should be prioritized in the ageing HIV population.

Keywords: Enfermedad cardiovascular; Enfermedad renal crónica; Envejecimiento; HIV; Tenofovir; VIH; ageing; cardiovascular disease; chronic kidney disease; tenofovir.

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Bone Diseases / complications*
  • Bone Diseases / epidemiology*
  • Cardiovascular Diseases / complications*
  • Cardiovascular Diseases / epidemiology*
  • Cross-Sectional Studies
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • Humans
  • Kidney Diseases / complications*
  • Kidney Diseases / epidemiology*
  • Male
  • Middle Aged
  • Prevalence
  • Risk Factors
  • Spain

Substances

  • Anti-HIV Agents